Trials / Completed
CompletedNCT00857532
Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
A Phase 2 Trial of Florbetapir F18 PET Imaging of β-amyloid in Parkinson's Disease Patients With Cognitive Impairment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Avid Radiopharmaceuticals · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | florbetapir F 18 | 10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2011-11-01
- Completion
- 2011-11-01
- First posted
- 2009-03-06
- Last updated
- 2013-03-11
- Results posted
- 2013-03-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00857532. Inclusion in this directory is not an endorsement.